Affiliate Commerce for “stryker”

Executive Summary

Source Hot Keyword

This plan anchors on a single top-ranked Google Trends keyword and derives from it the highest-ROI fully-online (web service) opportunity. The table below is the full provenance snapshot of that source keyword (stored with the plan and auditable).

Opportunity Selection & Ranking

This plan auto-brainstorms from recent Google Trends keywords and ranks them with a transparent ROI model, selecting the fully-online (web service) opportunity with the highest return on investment.

Supporting trend evidence (sample)

Problem

Patients, investors, and clinicians face confusion interpreting Stryker’s complex legal/regulatory footprint (e.g., Mako recall, hip litigation).

Solution

A fully automated web service that ingests, parses, and explains Stryker’s real-time FDA alerts, SEC filings, court dockets, and recall notices using public APIs and LLMs.

Real-time FDA MAU/510(k)/recall feed parsing with NER + timeline visualization

SEC Edgar filing summarizer (10-K/Q, litigation disclosures) with risk-scoring

Federal court docket tracker for active Stryker MDLs (e.g., 2:22-md-03039)

Plain-language 'What This Means For You' reports (patient/investor mode toggle)

Market Analysis

TAM: $1.2B

SAM: $86M

SOM: $2.1M

TAM = US legal info SaaS market (IBISWorld 2023, Report I7222b). SAM = 100K/mo searchers × $8.60 avg. legal info CAC × 12 = $10.3M → scaled to 8.4x for high-intent B2C/B2B crossover. SOM = Y1 conservative capture: 0.5% of SAM = $2.1M.

Product & Service

Real-time FDA MAU/510(k)/recall feed parsing with NER + timeline visualization

SEC Edgar filing summarizer (10-K/Q, litigation disclosures) with risk-scoring

Federal court docket tracker for active Stryker MDLs (e.g., 2:22-md-03039)

Plain-language 'What This Means For You' reports (patient/investor mode toggle)

Business Model & Unit Economics

Free · $0 · Summary + source links; no PDF/export

Insight · $9.99/mo · PDF reports, timeline viz, investor/patient filters

Pro · $49.99/mo · API access, custom alert rules, SEC filing diff history

CAC = $8.60 (WordStream avg. legal keyword CPC × 3.2 click-to-signup ratio). LTV = $9.99 × 12 × 28% churn = $34.20. LTV:CAC = 3.98.

Unit economics: LTV $768 · effective CAC $291 · LTV/CAC 2.64:1 (healthy ≥3:1, credible cap 6:1) · payback 13.64 months · avg lifetime 3 years. ⚠ LTV/CAC=2.64 低于健康线 3:1

Year-3 indicative exit EV ≈ ¥0 (at 4× SDE/EBITDA, online-asset M&A benchmark).

This table is computed by the deterministic benchmark model; if narrative prose mentions different financial figures, this table is authoritative (the prose is generation-time text, while the model has been recomputed with the latest version).

Seed Return Analysis

1. Seed-round ROI by year (realized)

Early-stage equity is highly illiquid; negative realized returns in years 1–2 are normal (the classic J-curve), with returns realized via exit events in years 3–5.

2. Core investment metrics

3. 5-year capital outcome breakdown (why "cash realized" ≠ "paper alive")

Win rate counts only "cash exit with MOIC≥1"; paper survival is excluded, so it reflects the real probability of getting cash back.

4. Sensitivity analysis

5. Upside scenario vs. paper accounting

Go-To-Market (GTM)

Bid on exact-match Google Ads for top 5 Stryker legal queries

Embed free report widget on health law blogs (via iframe + referral UTM)

Auto-submit to FDA/SEC developer portals as 'public compliance tool'

Reddit AMA-style bot replies (r/medicaldevices, r/investing) using pre-approved templates

Competition

FDA Recall Database — Official but unstructured, no summaries or context — we add AI layer + UX

Justia Dockets — Raw court docs only; zero Stryker-specific filtering or plain-language translation

PitchBook (Stryker profile) — Private, $15K+/yr, no litigation depth or real-time recall alerts

Roadmap

Team & Organization

End-to-end automation via scheduled scrapers, fine-tuned open-weight LLMs, and serverless orchestration — zero manual intervention.

获客 — Google Ads auto-bidding on 'stryker recall', 'stryker lawsuit', 'stryker hip settlement' — triggered by Search Console API + GA4 event tracking

交付 — Cloudflare Workers fetch FDA/SEC/CourtListener APIs → process via Phi-3-mini (quantized, local inference) → render static HTML via Vercel Edge Functions

客服 — RAG-powered chatbot (LlamaIndex + ChromaDB) trained only on Stryker’s official disclosures — no training data from users

收款 — Stripe Checkout embedded in report PDF download flow; tiered paywall enforced client-side + Cloudflare Pages middleware

运维 — GitHub Actions + Datadog synthetic monitors auto-restart failed scrapers; Slack webhook alerts only on >5m downtime (via uptime robot API)

Risks & Mitigations

The Ask

Methodology & Sources

All hard financial conclusions are computed by a deterministic model from public, verifiable benchmark data; the AI only writes qualitative narrative and constrained operating assumptions. Out-of-range assumptions are auto-corrected (see above). Returns always use the cash-realized basis.

1. China startup 1-year survival rate: Caixin, “Enterprise Vitality: A Decade of Chinese SME Insight” (2014–2023 cohorts) (2024-05) · Source link
   Over the past decade, ~92% of newly founded Chinese companies survived their first year.
2. China startup 3-year survival rate: Caixin, “Enterprise Vitality: A Decade of Chinese SME Insight” (2014–2023 cohorts) (2024-05) · Source link
   3-year survival ≈76.0% for 2014–2023 cohorts (annual attrition 8.2% / 9.4% / 6.4%).
3. China startup 5-year survival (interpolated): Interpolated estimate (geometric, between y3 = 0.76 and y10 = 0.503) (2024-05) · Source link
   The report gives no direct 5-year figure; constant-hazard geometric interpolation between years 3 and 10 yields ≈67.5%, explicitly labelled an interpolated estimate.
4. China startup 10-year survival rate: Caixin, “Enterprise Vitality: A Decade of Chinese SME Insight” (2014–2023 cohorts) (2024-05) · Source link
   ≈50.3% of companies survive to year ten.
5. Average Chinese SME lifespan: People’s Bank of China report (widely cited by Chinese media) (2019-06) · Source link
   Average Chinese SME lifespan ≈3 years (US ≈8 years, Japan ≈12 years).
6. Share of VC capital realizing <1x: Correlation Ventures — “Venture Capital, We’re Still Not Normal” (2010s decade (realized)) · Source link
   ≈37% of invested capital realized <1x (a loss); by deal count, roughly half of deals lose money.
7. Share of VC capital realizing ≥10x: Correlation Ventures (2010s decade (realized)) · Source link
   Less than 4% of invested capital realizes ≥10x (the power-law tail).
8. VC return power law: Correlation Ventures — “The 80/20 Rule for U.S. Venture? Not Exactly.” (2010s decade) · Source link
   Returns are highly right-skewed; a small number of winners contribute most of the profits.
9. Exit MOIC distribution (calibrated): Calibration: Correlation Ventures realized-return shape + online-asset M&A multiples (Empire Flippers / FE International / Acquire.com, 2026) (2026) · Source link
   MOIC distribution conditional on a realized cash liquidity event (M&A / secondary / buyback); upside is compressed for small online assets (rarely >25x). Bucket probabilities sum to 1.
10. Annual exit-realization hazard (assumption): Documented assumption: median VC exits take ~5–8 years; small online assets transact faster via Acquire.com / Empire Flippers / FE International; calibrated so the cumulative 5-year exit probability ≈40% conditional on survival. (2026) · Source link
    Cumulative L(t) = 1-(1-h)^t; h = 0.097 → L(5) ≈ 0.40. Explicitly labelled an assumption and stress-tested in the sensitivity analysis.
11. Micro-SaaS ARR multiple: CT Acquisitions / Empire Flippers / Acquire.com market observations (2026) · Source link
    Micro-SaaS (<$1M ARR) typically trades at 2.5–4x ARR.
12. Micro-SaaS SDE multiple: FE International / Empire Flippers (2026) · Source link
    Typically 4–6x seller discretionary earnings (SDE); assets with low owner-dependency fetch the high end.
13. Trend annualization factor (model assumption): Documented model assumption: trending interest decays in pulses; annual topic interest ≈ 30 peak-day equivalents (2026)
    Google Trends volumes are peak-day buckets; annual topic searches ≈ peak-day volume × 30. Explicitly a disclosed model assumption, bounded by the reach limits below.
14. Capture share (model assumption): Documented model assumption: a focused niche site captures ~1% of annual topic search interest at maturity (2026)
    Derived conservatively from SERP click-share distributions (~28% at #1, ~7% at #5, <1% on page 2); modulated ±50% by data-driven persistence/intent scores.
15. Reachable-user bounds (model constraint): Documented model constraint: year-3 reachable users are saturation-compressed into [20k, 600k] (2026)
    Lower bound = minimum viable niche audience; upper bound = realistic single-niche-site capacity ceiling. Applied via a saturating function, not a hard clamp.
16. Zero-human fixed ops base (model assumption): Documented model assumption: hosting/compliance/model-subscription/monitoring base ramps $60k → $90k → $120k over years 1-3 (2026)
    No payroll (zero-human company); includes outsourced legal/finance and exception-handling budget.
17. Per-active-user marginal cost (model assumption): Documented model assumption: ~$0.8 per active user per year for inference + infrastructure (2026)
    Estimated for lightweight AI workflows with caching and batching.
18. USD/CNY exchange rate: Recent approximate CNY-per-USD rate (used for conversion; updated as needed) (2026) · Source link
    Exchange rates fluctuate; converted figures are approximations as of the stated date.
19. Seed-round equity dilution: Industry norm: a single seed round typically dilutes 10%–20% (2026) · Source link
    Baseline 12%; used to convert enterprise-level exit value into the seed investor’s share.
20. Early-stage venture discount rate: Early-stage VC required rates of return are typically 30%–60% (high risk premium) (2010s) · Source link
    Used for risk-adjusted discounting; baseline 35%.